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Abstract 
Context: Adult body fat is associated with birth anthropometry suggesting a role for 
metabolic regulators including vitamin D and the adipokines - adiponectin and irisin – 
which have been reported to interact but, as yet, data remain controversial.   
 
Objective: To study (i) the relationship between vitamin D, its binding protein 
(VDBP) and the adipokines, adiponectin and irisin in mothers and neonates at birth 
and (ii) their effects on neonate anthropometric outcomes.  
 
Design: Cross-sectional study for healthy mothers with full-term and uncomplicated 
births. 
 
Setting: Primary care. 
 
Subjects: Seventy pairs of newly delivered neonates and their mothers. 
 
Main Outcomes Features: Biochemical markers from maternal and cord: VDBP, 
adiponectin, irisin, calcium, albumin, parathyroid hormone, 25OHD, 1,25(OH)2D. 
Maternal demographic and social characteristics and neonate anthropometric 
parameters were recorded.    
 
Results: Maternal VDBP levels (364.1±11.9 μg/ml) demonstrated a strong positive 
correlation with maternal adiponectin (4.4 ± 0.4 μg/ml) and irisin (308.8 ± 50.8 
ng/ml) concentrations which remained significant (p<0.001 and  p<0.041, 
respectively)  after adjustment with multiple parameters, including weeks of 
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gestation, maternal age, BMI. The finding of a strong association of VDBP (355.3 ± 
29.2 μg/ml) and adiponectin (11.9 ± 2.0 μg/ml) but not irisin (174.4 ± 26.0 ng/ml), 
was also evident in neonates (p=0.03 and p=0.94, respectively). No association was 
observed in both maternal and neonatal vitamin D, adiponectin and irisin.  
 
Conclusions: The main findings of this study are  i) the perspective of a potential 
independent interaction of VDBP and adiponectin in both mothers and neonates and 
ii) the lack of a causative model effect of both maternal/neonatal vitamin D status and 
adipokine profile on neonatal anthropometry at birth, as a surrogate marker of future 
metabolic health of the offspring. 
 
 
 
 
 
 
 
 
Precis  
In mother-neonate pairs at birth, adiponectin is independently associated vitamin D 
binding protein but not vitamin D status or significant anthropometric indices.    
 
 
 
 
  6 
 
  7 
1. Introduction 
  Vitamin D, recognised as essential for maintaining bone homeostasis and calcium 
absorption (1,2), has been recently established as a biological contributor in different 
cells and tissues (3-5). Despite having endogenous and dietary sources, 
hypovitaminosis D insufficiency and deficiency is common in all ages (6-8).   
   Numerous studies have investigated the association between vitamin D and disease 
onset or remission in a range of conditions including obesity, inflammation and 
insulin resistance (9-12). Recent advances in analytical capability have led to 
increasing interest in the roles of a wider range of molecules in the vitamin D 
metabolome (13,14). These advances, including accurate measurements of vitamin D 
forms, extend to the role of vitamin D-binding protein (VDBP), which primarily 
contributes to the transportation in the bloodstream of vitamin D metabolites (1). 
VDBP binds up to 80% of circulating vitamin D, playing a key role in regulating 
bioavailability and bioactivity of vitamin D, increasing its plasma half-life and 
modulating its distribution to target tissues. Therefore, its measurement along with 
vitamin D concentrations seems to be of importance (15). Moreover, VDBP has been 
hypothesized to exert regulatory immunological and metabolic actions (16).  
    Prior studies have investigated the relationship between vitamin D and adipokines. 
Adiponectin, secreted from adipose tissues, has key functions in energy homeostasis, 
including insulin action, food intake and metabolism (17). A proteomic study 
identified downregulation of adiponectin in vitamin D deficient obese children, and 
importantly a 12-month vitamin D3 supplementation course increased adiponectin 
levels (17). In isolated adipocytes, 1,25-(OH)2D3 increased adiponectin (17).  On the 
other hand, vitamin D supplementation did not increase adiponectin levels in a recent 
meta-analysis of 9 randomized controlled trials (RCTs) (18). Taken together, the 
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interaction between vitamin D and adiponectin may be condition-specific and affected 
by a number of mechanisms, including adipogenic gene expression and adipocyte 
apoptosis (19).   
Irisin, a myokine secreted primarily by skeletal muscle, is inversely correlated 
with vitamin D levels in small gestational age newborns (20). Previous reports linked 
irisin with circulating vitamin D levels (21).  To date, there have been no reports of 
associations between adiponectin or irisin and VDBP. 
  VDBP concentrations are known to increase in pregnancy. In addition, body 
weight and adipokine profile at birth, have been recently associated with fat mass in 
late childhood and adolescence, respectively (22). The potential role of VDBP as a 
mediator, confounder or neither in the metabolic regulation of maternal and offspring 
adipokine profile has not been investigated so far. 
  The primary aim of this study was to explore the association between adiponectin, 
irisin and VDBP concentrations in both mothers and neonates at birth of full-term and 
uncomplicated pregnancies. Secondary aims were to investigate the associations 
between neonatal anthropometric parameters, and maternal and neonatal adiponectin, 
irisin, VDBP, 25OHD and 1,25(OH)2D. The results of this study may provide insight 
in the physiological associations of VDBP beyond vitamin D, and possibly provide 
the basis for further research. 
 
2. Patients and methods 
2.1. Study population  
This was a cross-sectional study of pregnant women and their neonates, conducted 
from April 2014 until October 2015. Recruitment was discontinued from November 
2014 to March 2015 to minimize significant seasonal variation of study findings with  
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regard to maternal and neonatal vitamin D status. Pregnant women were recruited 
from the Maternity Unit of the First Department of Obstetrics and Gynaecology, 
Aristotle University, Thessaloniki, Greece, with latitude of 40°N. All women were 
fair skinned. Inclusion criteria were age>18 years, body mass index (BMI)≤30 kg/m2 
and full-term pregnancy (37-42
th 
 gestational week). Maternal non-inclusion criteria 
were BMI ≥30 kg/m2, primary hyperparathyroidism, secondary osteoporosis, 
osteomalacia, liver disease, hyperthyroidism, nephrotic syndrome, inflammatory 
bowel disease, rheumatoid arthritis, morbid obesity, gestational or pre-existing 
diabetes, active infection and use of medications affecting calcium or vitamin D 
homeostasis. Neonatal non-clusion criteria were prematurity ≤37 weeks of gestation, 
being small and large-for-gestational age neonates and the presence of severe 
congenital anomalies, as a result of one or more genetic, infectious, nutritional or 
environmental factors including heart and neural tube defects and Down syndrome. 
The study protocol conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki and was approved by the ethics committee of Medical School of Aristotle 
University of Thessaloniki. All mothers provided written informed consent for 
themselves and for their neonates. 
 
 2.2. Methods 
 2.2.1. Demographic and anthropometric data  
  At enrolment, demographic and social characteristics were recorded. Maternal pre-
pregnancy BMI was either normal (18–25 kg/m2) or overweight (25-30 kg/m2). We 
collected maternal, infant, and labor data from the medical records, collected 
umbilical cord blood samples at the time of delivery, and stored aliquots of plasma 
and serum at -70
o
C until assays were performed. We also evaluated neonatal 
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anthropometry at birth. All neonatal anthropometric measurements were performed 
by the same trained nurse, between 12h and 72h of age according to standard 
techniques (23,24). The following measurements were recorded: birth weight, height, 
neck-rump, upper arm, femur and knee heel lengths; head, chest, abdominal, upper 
arm and middle thigh circumferences, and abdominal skinfold thickness.  
The birth weight of the neonates was measured on regularly calibrated scales. 
Knee-heel length was measured with a hand-held BK5 infant knemometer (Force 
Technology, Brondby, Denmark). Instrument software calculated the mean of 10 
sequential readings and generated a printed report of all readings and the calculated 
mean. We also measured neonatal height to the nearest millimeter using an Ellard 
newborn lengthboard (Ellard Instrumentation Ltd., Seattle, WA). Abdominal, upper 
arm and middle thigh head, mid-upper arm, and maximal head circumferences were 
measured using a plastic encircling tape (Child GrowthFoundation, London, UK). 
Abdominal, skin fold was measured using Holtain calipers (Holtain, Crymych, UK). 
 
 2.1.2. Biochemical and hormonal assays 
 
 Blood samples were obtained from mothers by antecubital venipuncture 30–60 
minutes before delivery. Umbilical cord blood was collected immediately after 
clamping, from the umbilical vein. Calcium (mg/dl), albumin, parathyroid hormone 
(PTH) (pg/mL, 25OHD (ng/ml) 1,25(OH)2D (pg/ml), VDBP (μg/ml) adiponectin 
(μg/ml) and irisin (ng/ml) were measured in one batch at the end of the study. 
Corrected calcium was calculated based on total calcium and albumin concentrations 
using standard equation [Corrected calcium= 0.8 ×(4 − serum albumin)]. Biochemical 
analysis of total calcium and albumin were performed with standard methods using 
the Cobas INTEGRA clinical chemistry system (D-68298; Roche Diagnostics, 
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Mannheim, Germany). PTH was measured with electro-chemiluminescence 
immunoassay (ECLIA; Roche Diagnostics GmbA, Mannheim, Germany).  The 
reference range for PTH was 15 - 65 pg/ml, functional sensitivity 6.0 pg/ml, within-
run precision 0.6 - 2.8% and total precision 1.6 - 3.4%. VDBP, irisin and adiponectin 
were measured with enzyme-linked immunosorbent assay (ELISA) on a Synergy H1 
Hybrid reader and Gen5 software (BioTek, Winooski, VT, USA): Gc-Globulin/VDBP 
(AssayPro, St. Charles, MO, USA); irisin (MyBioSource, San Diego, CA, USA); 
adiponectin (R&D Systems, Minneapolis, MN, USA). 25OHD and 1,25(OH)2D were 
measured by radioimmunoassay using commercial kits obtained from DiaSorin 
Corporation (Stillwater MN, USA). Intra-assay and inter-assay variance was 5% and 
11% for 25(OH)D and 8% ,< 12%  for 1,25(OH)2D, respectively). Intra-assay and 
inter-assay variance was    <8% and <10% for adiponectin and <8% and <10%                
for irisin ,respectively. Detection limits for assays were 0.098 μg/ml for VDBP, 3.12 
ng/ml for irisin,0.039 μg/ml for adiponectin, 5 ng/ml -100 ng/ml for 25OHD and 7.5-
100 pg/ml for 1,25(OH)2D. 
  Vitamin D status (25OHD) was classified as sufficient or insufficient 
according to consensual Institute of Medicine criteria [sufficiency: 20-40 ng/ml (50-
100 nmol/L); insufficiency < 20 ng/ml (50 nmol/L) (25). 
 
2. 2. 3. Statistical Analysis 
   Continuous data are presented as mean ± standard error of the mean (SEM). 
Categorical data are presented as absolute numbers and/or frequencies. Kolmogorov-
Smirnov test was used to check the normality of distributions of continuous variables. 
Chi-square test was used for between group comparisons, in case of categorical 
variables. Independent samples t-test or Mann-Whitney test was used for between 
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group comparisons, in case of continuous variables. Spearman’s coefficient (rs) was 
used for binary correlations. Multiple linear logistic regression analysis (method 
“enter”) was used to identify independent associates for adiponectin, irisin levels or 
other parameters when needed. For the need of regression analysis, any of the 
included variables that did not follow normal distribution was logarithmically 
transformed. Statistical analysis was performed with SPSS 21 for Macintosh (IBM 
Corp., Armonk, NY). Significance was set at p<0.05 in all the tests. 
 
3. Results 
3.1. Description of the cohort and comparative data 
  Seventy pairs of newly delivered neonates and their mothers were included in 
this study. The demographic and anthropometric characteristics of the cohort are 
presented in Table 1. As selected, all women were non-obese (pre-pregnancy) and 
apparently healthy. Their educational level was elementary in 52 (74.3%) and 
secondary in 14 (20%), and unknown in 4 (5.7%) women. Eleven (15.7) women had 
previously given birth to one child; eight (11.4%) to two; one (1.4%) to three; and one 
(1.4%) to four children.  
  Thirty-seven (52.9%) women had received calcium supplementation during 
pregnancy, either 500 mg (n=30) or 1000 mg (n=7). None received vitamin D 
supplementation during pregnancy. Serum 25OHD levels were insufficient in 55 
(78.5%) women [27 (38.6%) women had levels between 10-19.9 ng/ml and 28 (40%) 
women had levels 5-9.9 ng/ml]. Maternal 25(OH) D levels were negatively correlated 
with elementary educational level (p=0.03) and height (p=0.04), but not with maternal 
BMI. 
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  Comparative biochemical and hormonal data between mothers and neonates 
are presented in Table 2. As expected, the neonates had lower PTH and higher 
corrected calcium levels compared with mothers. On the other hand, 25OHD, 
1,25(OH)2D and VDBP levels were not different between groups, with 1,25(OH)2D 
only marginally not reaching the level of statistical significance (p=0.057). 
Interestingly, adiponectin levels were higher, whereas irisin levels were lower in 
neonates than mothers. 
  When maternal and neonatal serum parameters [PTH, 25OHD, 1,25(OH)2D, 
VDBP, adiponectin and irisin] were compared according to the weeks of gestation 
(<37 vs. ≥37), maternal irisin levels were lower in the former group compared with 
the latter (153.3 vs. 402.5 ng/ml; p=0.006). When the median neonate weight (3205 g) 
was used as a cut-off, no statistically significant difference was observed in maternal 
and neonatal serum parameters between groups. 
 
3.2. Correlations of maternal parameters 
  A correlation matrix for maternal parameters only is presented in Table 3. As 
expected, corrected calcium was inversely correlated with PTH levels, and positively 
with 25OHD and 1,25(OH)2D; 25OHD levels also were positively correlated with 
1,25(OH)2D and height. PTH, 25OHD and 1,25(OH)2D levels were not correlated 
with VDBP, adiponectin or irisin levels. Notably, VDBP levels were positively 
correlated with adiponectin and irisin levels, whereas inversely with age. Adiponectin 
levels were inversely correlated with weight and BMI at term, and irisin levels 
positively with weight (Table 3). 
   After sequential adjustment for weeks of gestation (model 1), weeks of 
gestation and maternal age (model 2), weeks of gestation, maternal age and BMI 
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(term) (model 3), maternal adiponectin and irisin levels remained significantly 
positively associated with VDBP levels (Table 4 and 5, respectively). However, 
weeks of gestation did not remain significantly associated with irisin levels (Table 5). 
 
3.3. Correlations of neonatal parameters 
   A correlation matrix for neonatal parameters only is presented in Table 6. 
Corrected calcium was inversely correlated with PTH levels, but not with 25OHD and 
1,25(OH)2D levels. 25OHD levels were positively correlated with 1,25(OH)2D levels 
and upper arm length. VDBP levels were positively correlated with adiponectin, but 
not irisin levels. Irisin levels were inversely correlated with PTH levels and knee-heel 
length. 
   After sequential adjustment for weeks of gestation (model 1), weeks of 
gestation and neonate gender (model 2), weeks of gestation, neonatal gender and 
weight (model 3), neonatal adiponectin levels remained significantly positively 
associated with VDBP levels (Table 7). Νeonatal irisin remained non-significantly 
associated with VDBP levels, after similar sequential adjustment. 
 
3.4. Correlations between maternal and neonatal parameters 
   A correlation matrix between maternal and neonatal parameters is presented in 
Table 8. Maternal PTH levels were inversely correlated only with neonatal 25OHD 
levels. Maternal 25OHD levels were positively correlated with neonatal 25OHD and 
1,25(OH)2D levels, and upper arm length. Maternal 1,25(OH)2D levels were inversely 
correlated with neonatal irisin levels and positively with abdominal skin fold. 
Maternal VDBP levels were inversely correlated with neonatal height and upper arm 
length, but not adiponectin or irisin levels. Maternal adiponectin levels were inversely 
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correlated, albeit marginal, with neonatal weight. Maternal irisin levels were inversely 
correlated with neonatal 1,25(OH)2D levels and positively with knee-heel length. 
Notably, apart from 25OHD levels that were highly correlated between mothers and 
neonates, there was no correlation between maternal and neonatal levels of PTH, 
1,25(OH)2D, VDBP, PTH, adiponectin and irisin (Table 8). 
    Neonatal adiponectin and irisin remained non-significantly associated with 
maternal VDPB, after sequential adjustment for weeks of gestation (model 1), weeks 
of gestation and maternal age (model 2), weeks of gestation, maternal age and BMI 
(term) (model 3), weeks of gestation and neonatal gender (model 4), weeks of 
gestation, neonatal gender and neonatal weight (model 5). 
   Since upper arm length was associated with both maternal and neonatal 
25OHD and knee-heel length was associated with both maternal and neonatal irisin, 
we performed additional regression analyses with knee-heel length or upper arm 
length as dependent variables. Neonatal upper arm length remained significantly 
positively associated with maternal 25OHD after sequential adjustment for weeks of 
gestation (model 1), weeks of gestation and maternal age (model 2), weeks of 
gestation, maternal age and BMI (term) (model 3), and weeks of gestation, maternal 
age, BMI (term) and maternal VDBP (model 4; Table 9). On the other hand, neonatal 
upper arm length did not remain significantly associated with neonatal 25OHD after 
sequential adjustment for weeks of gestation, neonatal gender and neonatal weight 
and VDBP. Neonatal knee-heel length did not remain independently associated with 
maternal irisin levels after sequential adjustment for weeks of gestation, maternal age 
and BMI, or with neonatal irisin levels after sequential adjustment for weeks of 
gestation, neonatal gender and weight. 
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4. Discussion 
  This is the first study to investigate potential associations between vitamin D 
metabolites, VDBP and adiponectin (adipokine) and irisin (myokine) in mother-
neonate pairs and the associations between neonatal anthropometry and maternal-
neonatal vitamin D, adiponectin and irisin at birth. To the best of our knowledge, we 
provide here the first evidence of an association between VDBP and adiponectin 
levels in both mothers and neonates. On the other hand, no association was observed 
in both maternal and neonatal vitamin D metabolites, adiponectin and irisin.   
            Maternal VDBP levels demonstrated a positive association with maternal 
adiponectin and irisin concentrations, which remained significant after adjustment for 
multiple potential confounders. VDBP and adiponectin, but not irisin, also were 
independently associated in neonates. This finding raises consideration regarding the 
role of VDBP as a carrier protein or regulator of biological activity of adiponectin and 
irisin during pregnancy. The expected rise of VDBP in the pregnant state might also 
distort the association, but this finding was observed in neonates as well, at least for 
adiponectin. Mechanistic studies are required to elucidate whether VDBP plays a 
carrier or regulatory role for adiponectin and/or irisin during pregnancy.   
  This study also confirmed data from previous observational studies (26, 27) 
showing that cord blood adiponectin levels were higher than those observed in adults. 
This finding could be explained by the observed increase in adiposity with aging. The 
increase in adiposity is most evident in visceral adipose tissue, while there may be 
decreases in subcutaneous adipose tissue. being most evident in visceral adipose 
tissue, while there may be decreases in subcutaneous adipose tissue. This age-
associated change in body composition, where adiposity increases throughout midlife 
but decreases once late-life is reached, has been consistently found in several different 
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ethnic groups and may be influenced by dietary intake however, unlike many 
adipocyte derived factors, circulating adiponectin levels decrease with increasing 
adiposity (26,27).On the other hand, irisin concentrations were lower in neonates than 
mothers, a finding which has been previously observed in pathological conditions, 
including diabetes and obesity, as well as in uncomplicated pregnancy (28). 
Differences in neonate and adult muscle mass could explain the increased 
concentrations of maternal irisin compared to neonatal ones ,in this study. 
         As previously reported (29), there was no correlation between maternal 
circulating VDBP and PTH, 25OHD and 1,25(OH)2D concentrations. A high estrogen 
status such as pregnancy (29) is associated with high serum VDBP concentrations. 
Of note, a negative correlation of VDBP with age, was evident. Previous findings 
demonstrated, that serum VDBP concentrations are lower in post- than 
premenopausal women which could potentially be attributed to differences in 
estrogen status (30). However, the finding of age related of VDBP according to age 
within the same pregnant cohort warrants further investigation. 
Vitamin D metabolites were also not correlated with adiponectin and irisin in both 
mothers and neonates, although previous results, reported an association of 
adiponectin, advanced oxidation protein products and advanced glycation end-
products, with vitamin D status (31,32). However, as aforementioned, a recent meta-
analysis did not indicate any significant effect of vitamin D supplementation on 
adiponectin profile in the general non-pregnant population (18). 
  Our results are in accordance with recent findings by McManus et al. (33), 
who reported no correlations between maternal and neonatal 25OHD and adipokine 
concentrations at birth in both controls and women with gestational diabetes. Unlike 
the present population, McManus et al. population was vitamin D sufficient (33). 
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Although further studies are necessary, this finding may imply that vitamin D 
metabolites are not correlated with adiponectin irrespective of vitamin D status. 
  Regarding correlations between maternal and neonatal parameters, contrary to 
our findings, Luo et al. observed a positive correlation in adiponectin levels of 
maternal and fetal circulation (34). In our study however, no such association was 
observed for adiponectin and irisin across maternal-neonatal pairs, which possibly 
implies that neonatal adiponectin and irisin at birth are not substantially affected by 
maternal ones. The study of Luo et al. (34), investigated adiponectin concentrations 
in maternal (at 24-28 and 32-35 weeks of gestation) and fetal circulations, whereas 
our study assessed these adiponectin levels at birth. This difference in the time point 
of maternal-neonatal sampling might be the reason for the differences between the 
two studies. Similar to our findings, other authors observed no correlation between 
maternal and umbilical cord adiponectin concentrations (35), suggesting that 
adiponectin in cord blood is possibly of fetal origin. With regard to potential gender 
differences for adipokines in neonates, no significant differences in adiponectin levels 
were found between female and male neonates in a previous study (35). 
   Upper arm length was the only anthropometric parameter associated with both 
maternal and neonatal 25OHD, although this association attenuated for neonates after 
adjustment for potential confounders. Although lower mean neonatal knee-heel length 
at birth has been associated with lower maternal 25OHD levels at 28–32 weeks’ 
gestation (36), we were not able to confirm this association at birth. No consistent 
correlations were evident between maternal and neonatal adiponectin or irisin and 
neonatal anthropometry as well. 
    Although the present study was not designed for this purpose, it reported maternal 
and neonatal hypovitaminosis D in a sunny European area, with none receiving 
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vitamin D supplementation according to current guidelines (37). These results are 
consistent with previous larger scale findings from the same region (38,39). Of note, a 
similar pattern of distribution of hypovitaminosis D between maternal and neonatal 
25OHD concentrations was observed in both mothers and neonates being at 
insufficiency range (40-42).The lack of maternal vitamin D status with BMI could be 
attributed to the small study sample .In addition, previous findings on the association 
of maternal vitamin D levels and educational status (43), were also observed in this 
study. 
The main strength of our study relies on its originality. The absence of prior 
reports on associations between VDBP and adiponectin warrants further mechanistic 
research on the role of VDBP in bioavailability and bioactivity of adiponectin. This 
study, however, has certain limitations. First, while the sample size was relatively 
small, it was sufficiently powered to show significant differences regarding the main 
aim of the study. Second, the cross-sectional design of the study cannot prove a causal 
relationship. Third, all women were Caucasian, so our results cannot be safely 
generalized to other ethnicities, known to differ at least in adiponectin levels. 
Furthermore, multiple comparisons render some correlations prone to a false positive 
error. However, the association between VDBP and adiponectin and irisin remained 
robust after adjustment for potential confounders. Finally calcium intake was based 
on self-reporting and we did not systematically assess calcium intake with a validated 
questionnaire. 
 In conclusion, our study reports that neonatal anthropometry at birth was not 
associated with maternal or neonatal vitamin D concentrations, but suggests an 
independent association between VDBP and adiponectin in both mothers and 
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neonates, and between VDBP and irisin only in mothers. These findings warrant 
further research on the potential role of VDBP in regulating adiponectin and irisin. 
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Figure legends  
Figure 1. Scatter plot between adiponectin and vitamin D-binding protein in mothers 
(A) and neonates (B). A significant correlation is shown in both. 
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Table 1. Maternal and neonatal demographic and anthropometric characteristics. 
Maternal 
Number (n) 70 
Age (years) 31.9 ± 0.7 
Height (cm) 164.9 ± 0.7 
Weight; pre-pregnancy (kg) 67.6 ± 1.8 
Weight; term (kg) 81.4 ± 1.8 
BMI; pre-pregnancy (kg/m
2
) 24.9 ± 0.6 
BMI; term (kg/m
2
) 29.6 ± 0.7 
Weeks of gestation (n) 38.8 ± 0.2 
Smoking [n (%)] 10 (14.3) 
Alcohol consumption [n (%)] 8 (11.4) 
Previous live births [n (%)] 21 (30.0) 
Daily Calcium Supplementation [n (%)] 37 (52.9) 
Daily Calcium Supplementation (mg) 423 ± 44 
Neonatal 
Number (n) 70 
Gender; Males [n (%)] 38 (54.3) 
Height (cm) 50.5 ± 0.2 
Weight (g) 3292 ± 51 
Head Circumference (cm) 34.4 ± 0.3 
Chest Circumference (cm) 31.0 ± 0.2 
Abdominal Circumference (cm) 28.1 ± 0.3 
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Skin fold; abdominal (cm) 3.0 ± 0.2 
Upper Arm Circumference (cm) 9.8 ± 0.1 
Middle thigh Circumference (cm) 13.4 ± 0.1 
Upper Arm Length (cm) 13.7 ± 0.1 
Femur Length (cm) 9.9 ± 0.1 
Knee-Heel Length (cm) 9.2 ± 0.1 
Data are presented as mean ± standard error of the mean (SEM) for continuous variables and 
frequencies [numbers (%)] for categorical variables. 
Abbreviations: BMI, body mass index. 
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Table 2. Comparative maternal and neonatal biochemical and hormonal parameters 
 Mothers Neonates p-value * 
Corrected Calcium (mg/dl) 10.1 ± 0.1 11.7 ± 0.1 <0.001 
PTH (pg/ml) 27.2 ± 1.6 6.4 ± 0.2 <0.001 
25OHD (ng/ml) 18.3 ± 1.2 16.3 ± 1.0 0.217 
1,25(OH)2D (pg/ml) 51.9 ± 2.4 43.8 ± 3.6 0.057 
VDBP (μg/ml) 364.1 ± 11.9 355.3 ± 29.2 0.780 
Adiponectin (μg/ml) 4.4 ± 0.4 11.9 ± 2.0 <0.001 
Irisin (ng/ml) 
#
 308.8 ± 50.8 174.4 ± 26.0 0.041 
Data are presented as mean ± standard error of the mean (SEM) for continuous 
variables. 
* Independent sample t-test or Mann-Whitney test were used for between group 
comparisons. 
#
 n=61 for mothers; n= 42 for neonates 
Abbreviations: 1,25(OH)2D, 1,25(OH)2-Vitamin D; 25OHD, 25(OH)-Vitamin D; 
PTH, parathyroid hormone; VDBP, Vitamin D-binding protein. 
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Table 3. Correlations of maternal parameters. 
 
PTH  
(pg/ml) 
25ΟΗD  
(ng/ml) 
1,25(ΟΗ)2D 
(pg/ml) 
VDBP  
(μg/ml) 
Adiponectin  
(μg/ml) 
Irisin  
(ng/ml)
#
 
Age (years) 0.15 (0.22) -0.08 (0.51) -0.05 (0.68) -0.26 (0.04)* -0.23 (0.08) -0.06 (0.64) 
Height (cm) -0.08 (0.51) 0.26 (0.04)* -0.17 (0.16) 0.10 (0.40) -0.12 (0.35) 0.02 (0.83) 
Weight; pre-pregnancy (kg) -0.06 (0.61) 0.09 (0.46) 0.06 (0.06) -0.08 (0.51) -0.21 (0.09) 0.13 (0.31) 
Weight; term (kg) 0.03 (0.81) -0.01 (0.92) 0.01 (0.89) -0.04 (0.73) -0.28 (0.03)* 0.27 (0.047)* 
BMI; pre-pregnancy (kg/m
2
) -0.08 (0.53) 0.03 (0.76) 0.11 (0.11) -0.11 (0.39) -0.17 (0.18) 0.10 (0.43) 
BMI; term (kg/m
2
) -0.03 (0.83) -0.07 (0.59) 0.01 (0.92) -0.12 (0.33) -0.27 (0.04)* 0.17 (0.21) 
Weeks of gestation (n) -0.10 (0.49) 0.12 (0.41) 0.19 (0.19) -0.14 (0.33) 0.05 (0.72) 0.28 (0.06) 
Corrected calcium (mg/dl) -0.46 (<0.001)* 0.38 (0.002)* 0.28 (0.002)* 0.13 (0.28) -0.07 (0.55) -0.02 (0.85) 
PTH (pg/ml) - -0.46 (<0.001)* 0.00 (0.97) -0.03 (0.77) 0.17 (0.15) 0.10 (0.43) 
25(ΟΗ)D (ng/ml) - - 0.49 (<0.001)* 0.01 (0.92) 0.10 (0.39) 0.00 (0.98) 
1,25(ΟΗ)2D (pg/ml) - - - 0.21 (0.07) 0.08 (0.51) 0.25 (0.05) 
VDBP (μg/ml) - - - - 0.41 (0.001)* 0.30 (0.02)* 
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Adiponectin (μg/ml) - - - - - 0.04 (0.73) 
Data are presented as Spearman’s correlation (p-value). 
*: Statistically significant correlation. 
 
#
 n=61 
Abbreviations: 1,25(OH)2D, 1,25(OH)2-Vitamin D; 25OHD, 25(OH)-Vitamin D; BMI, body mass index; PTH, parathyroid hormone; VDBP, Vitamin 
D-binding protein. 
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Table 6. Correlations of neonatal parameters. 
 
PTH  
(pg/ml) 
25(ΟΗ)D 
(ng/ml) 
1,25(ΟΗ)2D 
(pg/ml) 
VDBP  
(μg/ml) 
Adiponectin  
(μg/ml) 
Irisin  
(ng/ml)
#
 
Height (cm) 0.04 (0.69) 0.06 (0.62) 0.16 (0.19) 0.05 (0.66) -0.11 (0.40) 0.06 (0.69) 
Weight (g) 0.08 (0.48) 0.00 (0.98) 0.03 (0.78) 0.21 (0.09) 0.01 (0.95) -0.08 (0.64) 
Head Circumference (cm) -0.09 (0.43) 0.08 (0.52) 0.17 (0.17) -0.01 (0.90) -0.13 (0.32) -0.29 (0.06) 
Chest Circumference (cm) -0.06 (0.63) 0.20 (0.12) 0.15 (0.22) 0.05 (0.69) 0.00 (0.98) -0.11 (0.53) 
Abdominal Circumference (cm) -0.02 (0.83) 0.21 (0.11) 0.12 (0.33) 0.10 (0.42) 0.10 (0.42) -0.17 (0.30) 
Skin fold; abdominal (cm) 0.19 (0.11) 0.08 (0.54) -0.04 (0.70) -0.16 (0.22) 0.19 (0.14) 0.12 (0.45) 
Upper Arm Circumference (cm) 0.09 (0.43) -0.02 (0.85) 0.16 (0.20) 0.30 (0.02)* 0.10 (0.43) -0.24 (0.13) 
Middle thigh Circumference 
(cm) 
0.04 (0.72) 0.16 (0.22) 0.03 (0.81) 0.08 (0.50) 0.03 (0.79) 0.00 (0.97) 
Upper Arm Length (cm) -0.11 (0.35) 0.30 (0.02)* 0.20 (0.11) 0.23 (0.07) -0.06 (0.60) 0.05 (0.74) 
Femur Length (cm) 0.01 (0.89) 0.04 (0.74) 0.06 (0.62) 0.05 (0.67) -0.13 (0.32) -0.06 (0.68) 
Knee-Heel Length (cm) 0.00 (0.97) -0.21 (0.10) -0.07 (0.57) 0.02 (0.86) -0.13 (0.32) -0.34 (0.04)* 
Corrected Calcium (mg/dl) -0.32 (0.01)* 0.10 (0.42) 0.00 (0.96) -0.16 (0.20) -0.29 (0.02)* 0.06 (0.68) 
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PTH (pg/ml) - -0.19 (0.12) -0.06 (0.63) 0.10 (0.41) 0.08 (0.51) -0.31 (0.049)* 
25(ΟΗ)D (ng/ml) - - 0.58 (<0.001)* 0.00 (0.96) -0.03 (0.78) 0.07 (0.63) 
1,25(ΟΗ)2D (pg/ml) - - - 0.11 (0.36) 0.03 (0.77) -0.18 (0.24) 
VDBP (μg/ml) - - - - 0.28 (0.03)* 0.01 (0.94) 
Adiponectin (μg/ml) - - - - - -0.00 (0.97) 
Data are presented as Spearman’s correlation (p-value). 
*: Statistically significant correlation 
#
 n=42 
Abbreviations: 1,25(OH)2D, 1,25(OH)2-Vitamin D; 25OHD, 25(OH)-Vitamin D; PTH, parathyroid hormone; VDBP, Vitamin D-binding protein. 
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Table 8. Correlations between maternal and neonatal parameters. 
  Maternal parameters 
 
 
PTH  
(pg/ml) 
25(ΟΗ)D 
(ng/ml) 
1,25(ΟΗ)2D 
(pg/ml) 
VDBP  
(μg/ml) 
Adiponectin  
(μg/ml) 
Irisin  
(ng/ml)
#
 
N
eo
n
a
ta
l 
p
a
ra
m
et
er
s 
Height (cm) 0.00 (0.98) 0.14 (0.24) 0.11 (0.36) -0.29 (0.04)* -0.17 (0.18) 0.17 (0.18) 
Weight (g) 0.07 (0.57) 0.04 (0.72) 0.13 (0.28) -0.15 (0.22) -0.25 (0.049)* 0.05(0.66) 
Head Circumference (cm) 0.13 (0.29) 0.17 (0.18) 0.12 (0.31) -0.11 (0.36) 0.06 (0.61) 0.20 (0.12) 
Chest Circumference (cm) -0.10 (0.40) 0.22 (0.07) 0.10 (0.43) -0.12 (0.31) -0.21 (0.09) 0.12 (0.35) 
Abdominal Circumference (cm) -0.04 (0.73) 0.13 (0.27) 0.08 (0.53) -0.20 (0.10) -0.15 (0.24) 0.06 (0.60) 
Skin fold; abdominal (cm) 0.05 (0.66) 0.16 (0.20) 0.28 (0.02)* 0.12 (0.32) 0.09 (0.47) 0.03 (0.80) 
Upper Arm Circumference (cm) 0.06 (0.62) 0.04 (0.73) 0.07 (0.54) -0.05 (0.68) -0.15 (0.24) 0.05 (0.70) 
Middle thigh Circumference (cm) 0.02 (0.89) 0.12 (0.33) 0.03 (0.77) -0.04 (0.73) -0.01 (0.91) 0.11 (0.38) 
Upper Arm Length (cm) -0.11 (0.35) 0.36 (0.004)* 0.01 (0.88) -0.31 (0.01)* -0.19 (0.12) 0.10 (0.43) 
Femur Length (cm) -0.02 (0.81) 0.03 (0.79) 0.10 (0.44) 0.05 (0.64) -0.01 (0.97) 0.14 (0.27) 
Knee-Heel Length (cm) 0.02 (0.81) 0.01 (0.89) 0.19 (0.11) 0.11 (0.36) -0.01 (0.91) 0.27 (0.04)* 
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Corrected Calcium (mg/dl) -0.09 (0.46) 0.00 (0.97) 0.19 (0.11) 0.19 (0.11) 0.00 (0.96) 0.18 (0.16) 
PTH (pg/ml) 0.16 (0.18) -0.18 (0.15) -0.03 (0.80) 0.09 (0.43) 0.22 (0.07) -0.23 (0.06)* 
25(ΟΗ)D (ng/ml) -0.46 (<0.001)* 0.82 (<0.001)* 0.23 (0.07) -0.14 (0.28) 0.22 (0.09) -0.10 (0.44) 
1,25(ΟΗ)2D (pg/ml) -0.22 (0.08) 0.54 (<0.001)* 0.23 (0.06) 0.01 (0.92) 0.20 (0.12) -0.27 (0.04)* 
VDBP (μg/ml) 0.19 (0.12) -0.06 (0.66) -0.12 (0.32) 0.01 (0.90) 0.14 (0.28) -0.11 (0.39) 
Adiponectin (μg/ml) 0.06 (0.59) 0.04 (0.72) -0.14 (0.26) -0.03 (0.82) 0.06 (0.61) -0.12 (0.35) 
Irisin (ng/ml)
#
 -0.01 (0.90) -0.11 (0.47) -0.44 (0.004)* -0.10 (0.54) 0.00 (0.95) -0.11 (0.48) 
Data are presented as Spearman’s correlation (p-value). 
*: Statistically significant correlation 
#
 n=61 for mothers; N= 42 for neonates 
Abbreviations: 1,25(OH)2D, 1,25(OH)2-Vitamin D; 25OHD, 25(OH)-Vitamin D; PTH, parathyroid hormone; VDBP, Vitamin D-binding protein. 
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Table 4. Sequential models of linear logistic regression analysis evaluating independent 
associates of maternal adiponectin levels (μg/ml). 
Variable 
Unstandardized 
β 
Standardized 
β 
p-value 
95% CI for 
β 
Model 1     
Maternal VDBP (μg/ml) 0.02 0.41 0.005 0.01 – 0.03 
Weeks of Gestation 1.01 0.14 0.31 -0.92 – 2.97 
Model 2     
Maternal VDBP (μg/ml) 0.02 0.38 0.011 0.01 – 0.03  
Weeks of Gestation 1.00 0.15 0.29 -0.92 – 3.00 
Maternal age (years) -0.07 -0.14 0.34 -0.22 – 0.08 
Model 3     
Maternal VDBP (μg/ml) 0.02 0.35 0.026 0.01 – 0.03 
Weeks of Gestation 0.74 0.10 0.47 -1.32 – 2.80 
Maternal age (years) -0.04 -0.07 0.64 -0.21 – 0.13 
Maternal BMI; term 
(kg/m
2
) 
-0.07 -0.15 0.33 -0.23 – 0.08 
Weeks of gestation was rated as 0 for <38, and 1 for ≥38, respectively. 
Abbreviations: VDBP, Vitamin D-binding protein. 
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Table 5. Sequential models of linear logistic regression analysis evaluating independent 
associates of maternal irisin levels (ng/ml)
 #
. 
Variable 
Unstandardized 
β 
Standardized 
β 
p-value 
95% CI for 
β 
Model 1     
Maternal VDBP (μg/ml) 2.49 0.39 0.007 0.72 – 4.26 
Weeks of Gestation 269.8 0.27 0.062 
-14.5 – 
554.1 
Model 2     
Maternal VDBP (μg/ml) 2.29 0.36 0.016 0.44 – 4.13 
Weeks of Gestation 263.2 0.26 0.07 
-22.9 – 
549.4 
Maternal age (years) -8.06 -0.12 0.42 -29.9 – 12.7 
Model 3     
Maternal VDBP (μg/ml) 2.33 0.37 0.015 0.47 – 4.18 
Weeks of Gestation 278.7 0.28 0.06 -7.1 – 564.6 
Maternal age (years) -14.31 -0.19 0.22 -37.7 – 9.08 
Maternal BMI; term 
(kg/m
2
) 
2.72 0.04 0.79 -17.8 – 23.2 
Weeks of gestation was rated as 0 for <38, and 1 for ≥38, respectively. 
#
 n=61 for mothers 
Abbreviations: VDBP, Vitamin D-binding protein. 
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Table 7. Sequential models of linear logistic regression analysis evaluating independent 
associates of neonatal adiponectin levels (μg/ml). 
Variable 
Unstandardized 
β 
Standardized 
β 
p-value 
95% CI for 
β 
Model 1     
Neonatal VDBP (μg/ml) 0.05 0.51 <0.001 0.02 – 0.07 
Weeks of Gestation 7.41 0.19 0.15 
-2.70 – 
17.53 
Model 2     
Neonatal VDBP (μg/ml) 0.05 0.55 <0.001 0.03 – 0.07 
Weeks of Gestation 6.20 0.16 0.25 
-4.61 – 
17.01 
Neonatal gender 7.31 0.20 0.16 
-2.91 – 
17.53 
Model 3     
Neonatal VDBP (μg/ml) 0.05 0.54 <0.001 0.02 – 0.07 
Weeks of Gestation 7.77 0.20 0.17 
-3.51 – 
19.04 
Neonatal gender 5.16 0.14 0.35 
-5.95 – 
16.27 
Neonatal weight (g) -0.01 -0.14 0.32 -0.02 – 0.01 
Weeks of gestation was rated as 0 for <38, and 1 for ≥38, respectively. 
Boys were rated as 0, and girls as 1 within gender. 
Abbreviations: VDBP, Vitamin D-binding protein. 
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Table 9. Sequential models of linear logistic regression analysis evaluating independent 
associates of neonatal upper arm length (μg/ml). 
Variable 
Unstandardized 
β 
Standardized 
β 
p-value 
95% CI for 
β 
Model 1     
Maternal 25OHD (ng/ml) 0.04 0.42 0.005 0.01 – 0.07 
Weeks of Gestation -0.05 -0.02 0.87  -0.68 – 0.58 
Model 2     
Maternal 25OHD (ng/ml) 0.04 0.45 0.003 0.02 – 0.07 
Weeks of Gestation -0.08 -0.04 0.80 -0.71 – 0.55 
Maternal age (years) 0.03 0.17 0.23 -0.02 – 0.07 
Model 3     
Maternal 25OHD (ng/ml) 0.04 0.45 0.004 0.02 – 0.07 
Weeks of Gestation -0.04 -0.02 0.90 -0.71 – 0.63 
Maternal age (years) 0.02 0.13 0.40 -0.03 – 0.08 
Maternal BMI; term 
(kg/m
2
) 
0.01 0.05 0.72 -0.04 – 0.06 
Model 4     
Maternal 25OHD (ng/ml) 0.04 0.45 0.005 0.01 – 0.07 
Weeks of Gestation -0.04 -0.02 0.92 -0.71 – 0.64 
Maternal age (years) 0.02 0.14 0.38 -0.03 – 0.08 
Maternal BMI; term 
(kg/m
2
) 
0.01 0.06 0.67 -0.04 – 0.06 
Maternal VDBP (μg/ml) 0.001 0.05 0.73 
-0.004 – 
0.005 
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Weeks of gestation was rated as 0 for <38, and 1 for ≥38, respectively. 
Abbreviations: 25OHD, 25(OH)-Vitamin D; VDBP, Vitamin D-binding protein. 
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